Media Relations News Releases Year: - Any -201820172016 Items per page 102550 Jun 28, 2018 Summary ToggleNovartis presents new data demonstrating long-term efficacy, safety and tolerability of Aimovig® (erenumab) in patients with chronic and episodic migraine Jun 27, 2018 Summary ToggleGlobal study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month Jun 27, 2018 Summary ToggleGlobal study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month Jun 1, 2018 Summary ToggleNovartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine May 17, 2018 Summary ToggleNovartis and Amgen announce FDA approval of Aimovig™ (erenumab), a novel treatment developed specifically for migraine prevention May 15, 2018 Summary ToggleNovartis successfully completes acquisition of AveXis, Inc. May 11, 2018 Summary ToggleNovartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis May 1, 2018 Summary ToggleKymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma Apr 17, 2018 Summary ToggleNovartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials Apr 17, 2018 Summary ToggleNovartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab) for migraine patients with multiple treatment failures Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Page 4 … Next page Next Last page Last
